A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (NCT07218029)
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can treat symptoms of PAH but do not stop PAH from getting worse. Sotatercept is a study medicine designed to treat PAH. It is a targeted therapy, which is a treatment that works on certain proteins that play a role in causing PAH. This is a long-term follow-up (LTFU) study. People who took part in certain other studies testing sotatercept for PAH may be able to join this study. The goal of this study is to learn about the long-term safety of sotatercept and if people tolerate it when taken with standard PAH treatment over a longer period of time.
Who can join: Review the eligibility criteria below.
Location: Pulmonary Associates, PA ( Site 1008) — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (134 Sites)
Showing the first 25 of 134 sites.
- Pulmonary Associates, PA ( Site 1008) — Phoenix, Arizona
- Arizona Pulmonary Specialists ( Site 1010) — Scottsdale, Arizona
- University of Arizona ( Site 1006) — Tucson, Arizona
- University of California San Diego Health ( Site 1002) — La Jolla, California
- UC Irvine Health Medical Center ( Site 1086) — Orange, California
- UC Davis - Medial Center ( Site 1064) — Sacramento, California
- UCSF Helen Diller Medical Center at Parnassus Heights ( Site 1019) — San Francisco, California
- Jeffrey S. Sager, MD Medical Corporation ( Site 1060) — Santa Barbara, California
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 1028) — Torrance, California
- University of Colorado Hospital ( Site 1013) — Aurora, Colorado
- George Washington University Medical Faculty Associates ( Site 1025) — Washington D.C., District of Columbia
- Mayo Clinic Jacksonville ( Site 1045) — Jacksonville, Florida
- AdventHealth Orlando ( Site 1058) — Orlando, Florida
- Tampa General Hospital ( Site 1043) — Tampa, Florida
- University of Kansas Medical Center ( Site 1020) — Kansas City, Kansas
- Norton Pulmonary Specialists ( Site 1066) — Louisville, Kentucky
- Johns Hopkins University ( Site 1036) — Baltimore, Maryland
- Tufts Medical Center ( Site 1012) — Boston, Massachusetts
- Brigham and Women's Hospital ( Site 1014) — Boston, Massachusetts
- University of Minnesota ( Site 1062) — Minneapolis, Minnesota
- University Of Nebraska Medical Center ( Site 1053) — Omaha, Nebraska
- Weill Cornell Medical Center ( Site 1046) — New York, New York
- Duke University Medical Center ( Site 1026) — Durham, North Carolina
- The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001) — Cincinnati, Ohio
- University of Cincinnati Medical Center ( Site 1035) — Cincinnati, Ohio
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Arterial Hypertension
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) — Aurora, Colorado
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension — Phoenix, Arizona
- Pulmonary Vascular Disease Phenomics Program PVDOMICS — Tucson, Arizona
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) — Jacksonville, Florida
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension — Aurora, Colorado
- ADAPT - A Patient Registry of the Real-world Use of Orenitram® — Fresno, California
Explore by condition: All Pulmonary Arterial Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.